TAT-GluA2 3Y 是一种可通过 HIV-1 TAT 蛋白结构域穿过细胞膜、透过血脑屏障的 AMPA 受体抑制多肽,可阻断 AMPA 受体的内吞作用(包括 GluA1/GluA2 亚基的内化),其机制为破坏与 AP2、Brag2 和 Syt3-GluA2 复合物的相互作用,同时还能抑制长时程抑制,并可阻断低氧介导的 AMPAR 内化、减轻 A1R 诱导的持续性突触抑制、减少脑缺血体积、神经功能缺损及空间记忆缺损,还可阻断 NLRP3 缺失对恐惧泛化的作用、抑制苯丙胺诱导的行为/神经化学敏化、削弱吗啡的非条件刺激-条件刺激关联并促进吗啡 CPP 的消退,因此可用于恐惧泛化、缺血性脑卒中、低氧、药物成瘾及阿片类成瘾的相关研究。
产品编号: MS-X19336 纯度: 99.93% CAS No.: 1404188-93-7 分子式: C115H185N43O29 分子量: 2633.97
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

TAT-GluA2 3Y 是一种可通过 HIV-1 TAT 蛋白结构域穿过细胞膜、透过血脑屏障的 AMPA 受体抑制多肽,可阻断 AMPA 受体的内吞作用(包括 GluA1/GluA2 亚基的内化),其机制为破坏与 AP2、Brag2 和 Syt3-GluA2 复合物的相互作用,同时还能抑制长时程抑制,并可阻断低氧介导的 AMPAR 内化、减轻 A1R 诱导的持续性突触抑制、减少脑缺血体积、神经功能缺损及空间记忆缺损,还可阻断 NLRP3 缺失对恐惧泛化的作用、抑制苯丙胺诱导的行为/神经化学敏化、削弱吗啡的非条件刺激-条件刺激关联并促进吗啡 CPP 的消退,因此可用于恐惧泛化、缺血性脑卒中、低氧、药物成瘾及阿片类成瘾的相关研究。

生物实验数据

生物活性 TAT-GluA2 3Y is a blood-brain barrier-permeable AMPA receptor inhibitory peptide that crosses the cell membrane via the HIV-1 TAT protein domain; it blocks AMPA receptor endocytosis, including internalization of GluA1/GluA2 subunits, by disrupting interactions with AP2, Brag2, and the Syt3-GluA2 complex, while also inhibiting long-term depression, and it blocks hypoxia-mediated AMPAR internalization, alleviates A1R-induced persistent synaptic depression, and reduces cerebral ischemic volume, neurological deficits, and spatial memory deficits; moreover, it blocks the effect of NLRP3 deficiency on fear generalization, inhibits amphetamine-induced behavioral/neurochemical sensitization, attenuates the unconditioned stimulus-conditioned stimulus association of morphine, and promotes the extinction of morphine CPP, making it useful for research on fear generalization, ischemic stroke, hypoxia, drug addiction, and opioid addiction.
IC50 & Target

AMPA Receptor

 

A1R

 

体外研究
(In Vitro)

Tat-GluA2-3Y (2 μM; 1 h pre-incubation) 可阻断网格蛋白介导的内吞作用,从而在原代培养的大鼠海马神经元中抑制 A1R 激动剂和缺氧诱导诱导的 GluA2 和 GluA1 AMPAR 内化,抑制 A1R 激动剂诱导的表面 GluA2 和 GluA1 AMPAR 水平降低。
Tat-GluA2-3Y (2 μM; 1 h pre-incubation) 可在大鼠海马脑片中阻止 A1R 激动剂诱导的 GluA2 AMPAR 内化。
Tat-GluA2-3Y peptide (2 μM) 可部分阻断网格蛋白介导的 GluA2 内化,从而减轻大鼠海马 CA3-CA1 突触中 A1R 激动剂诱导的持续性突触抑制。

体内研究
(In Vivo)

TAT-GluA2 3Y (4.32 μM/kg;腹腔注射;单次给药) 可阻断 NLRP3 敲除诱导的小鼠恐惧泛化,恢复海马 AMPA 受体 1 在 ser831 位点的磷酸化水平,并降低磷酸化 CaMKII 水平。
TAT-GluA2 3Y (5 mg/kg;腹腔注射;多次给药) 可破坏 Syt3 与 GluA2 的相互作用,提高 GluA2 的表面表达水平,抑制 CP-AMPAR 的形成,使大脑中动脉闭塞/再灌注 (MCAO/R) 诱导缺血性脑卒中的雄性 SD 大鼠的脑缺血体积减少约 40%-50%,改善神经功能,并增强其长期感觉运动及认知功能的恢复。
TAT-GluA2 3Y (1.5 nM/g;静脉注射;5 次 (每次右旋安非他明注射前 1 次,每 2 天 1 次)) 可阻断雄性 SD 大鼠中安非他明诱导的行为及神经化学敏化的诱导、维持与表达。
TAT-GluA2 3Y (15 pM;双侧微注射至腹侧被盖区 (VTA);共 5 次 (每次 d-苯丙胺注射前 1 次,每 2 天 1 次)) 可抑制雄性 SD 大鼠中苯丙胺诱导的行为敏化的维持与表达,但不抑制其诱导。
TAT-GluA2 3Y (按 1.5-2.25 nM/g 剂量静脉注射;每次吗啡条件化训练前 1 小时给药) 与吗啡在吗啡条件性位置偏爱 (CPP) 获得阶段联合给药,可促进偏好的快速消退,但不影响 CPP 的诱导、表达、维持或复燃。
TAT-GluA2 3Y (2.25 nM/g;静脉注射;每次食物条件化训练前 1 小时) 对大鼠食物诱导的条件位置偏好的诱导、消退及复建都无影响。

Animal Model: C57BL/6J background NLRP3 knockout (male, 8-10 weeks old)
Dosage: 4.32 μM/kg
Administration: i.p.; single dose
Result: Blocked the NLRP3 deprivation effect on fear generalization, as evidenced by a significant reduction in CS- freezing levels compared to untreated NLRP3 KO mice.
Left basal and CS+ freezing levels comparable between treated and untreated groups.
Recovered the hippocampal expression of phosphorylated AMPA receptor 1 at ser831.
Decreased phosphorylated CaMKII levels.
Left phosphorylated PKA levels unchanged.
Animal Model: Sprague-Dawley (male, 250-300 g, middle cerebral artery occlusion/reperfusion model)
Dosage: 5 mg/kg
Administration: i.p.; multiple doses (1 h before MCAO/R, 1 h after MCAO/R, 1 h before each behavioral test on days 3, 5, 7, 14, 21, 22, 23, 24, 25, 26, 27 post-MCAO/R)
Result: Reduced Syt3-GluA2 co-immunoprecipitation levels in penumbral tissue by ~90% compared with saline controls at 6 h post-MCAO/R.
Reduced ischemic volume to ~17% of total brain volume when administered 1 h before MCAO/R, compared with ~27% in scrambled peptide controls; reduced ischemic volume to ~20% when administered 1 h after MCAO/R.
Reduced mNSS scores to ~5 when administered 1 h before MCAO/R, and ~7 when administered 1 h after MCAO/R, compared with ~12 in scrambled peptide controls at 24 h post-reperfusion.
Increased surface GluA2 protein levels by ~40% in penumbral tissue at 6 h post-MCAO/R, compared with scrambled peptide controls, while intracellular GluA2 levels were reduced by ~40%.
Reduced AMPAR-mediated excitatory postsynaptic current amplitude reduction by Naspm to ~20%, compared with ~50% reduction in scrambled peptide controls.
Increased rotarod test latency to fall to ~220 s by day 21 post-MCAO/R, compared with ~150 s in scrambled peptide controls.
Reduced adhesive removal test contact time to ~10 s, and removal time to ~15 s by day 21 post-MCAO/R, compared with ~30 s and ~40 s, respectively, in scrambled peptide controls.
Reduced Morris water maze escape latency to ~20 s by day 26 post-MCAO/R, compared with ~30 s in scrambled peptide controls; increased platform crossings to ~3 times, compared with ~1 time in scrambled peptide controls.
Animal Model: Sprague-Dawley (male, 250-275 g, amphetamine-induced behavioural sensitization model)
Dosage: 1.5 nM/g
Administration: i.v.; 5 times (once before each d-amphetamine injection every second day)
Result: Blocked the induction of locomotor sensitization.
Attenuated d-amphetamine-induced dopamine efflux in the NAcc on day 9 to 278% of baseline, compared to 633% on day 1.
Reduced the locomotor response to the d-amphetamine challenge significantly compared to vehicle or scrambled peptide control groups, with no significant difference from drug-naive rats.
Blocked neurochemical sensitization, with d-amphetamine-induced dopamine efflux in the NAcc significantly lower than scrambled peptide control.
Animal Model: Sprague-Dawley (male, 250-275 g, amphetamine-induced behavioural sensitization model)
Dosage: 15 pM
Administration: bilateral microinjection into VTA; 5 times (once before each d-amphetamine injection every second day)
Result: Did not affect the induction of locomotor sensitization, with significant increases in cumulative 30-min distance travelled from day 1 to day.
Reduced the locomotor response to the d-amphetamine challenge significantly compared to vehicle or scrambled peptide control groups, blocking the maintenance and expression of behavioural sensitization.
Animal Model: Sprague-Dawley (male, 220-240 g at arrival, morphine-induced conditioned place preference model)
Dosage: 1.5 nM/g; 2.25 nM/g
Administration: i.v.; 1 h before each morphine conditioning session
Result: Had no effect on induction, initial expression, or maintenance of morphine-induced CPP, with rats maintaining a significant preference for the morphine-associated compartment in bi-weekly tests over 8 weeks.
Greatly facilitated extinction: rats treated with 1.5 nmol/g or 2.25 nmol/g failed to display a consistent preference for the morphine-paired compartment across 11 extinction days, whereas saline or scrambled peptide controls maintained preference until days 9 and 11 respectively.
Had no effect on morphine-induced reinstatement of CPP, with all groups showing a significant preference for the morphine-associated compartment during retesting.
Animal Model: Sprague-Dawley (male, weight maintained at 90% of standard growth curve, food-induced conditioned place preference model)
Dosage: 2.25 nM/g
Administration: i.v.; 1 h before each food conditioning session
Result: Had no effect on induction, extinction, or reinstatement of food-induced CPP.
All groups displayed a significant preference for the food-associated compartment during initial testing, extinguished their preference within 15 days, and showed significant reinstatement after exposure to a Froot Loop, with no group differences detected via two-way ANOVA for any phase.
性状 固体
颜色 White to off-white

化学信息

分子量 2633.97
分子式 C115H185N43O29
CAS No. 1404188-93-7

储存&溶解度

储存方式

Sealed storage, away from moisture and light, under nitrogen

Powder -80°C 2 years
-20°C 1 year

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

H2O 中的溶解度 : 100 mg/mL (37.97 mM; 超声助溶)

可选溶剂浓度1 mg5 mg10 mg25 mg
H2O1 mM0.3797 mL1.8983 mL3.7966 mL9.4914 mL
5 mM0.0759 mL0.3797 mL0.7593 mL1.8983 mL
10 mM0.0380 mL0.1898 mL0.3797 mL0.9491 mL
15 mM0.0253 mL0.1266 mL0.2531 mL0.6328 mL
20 mM0.0190 mL0.0949 mL0.1898 mL0.4746 mL
25 mM0.0152 mL0.0759 mL0.1519 mL0.3797 mL
30 mM0.0127 mL0.0633 mL0.1266 mL0.3164 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础